System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Angèle Soria is an expert in Dermatology at Tenon Hospital (France). As of October 2026, ScienceLeadR ranks Angèle Soria in the top 1% of experts worldwide for Dermatitis, Hypersensitivity and COVID-19. Angèle Soria has authored 325 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 5 of them ongoing. SLR score: 1,250 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Angèle Soria Tenon Hospital France
1 250 ScienceLeadR Reputation 1250

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Immunology - Infectiology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Tenon Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 325

Citations

Citations: 4 340 1st author: 30 Last author: 88 Unique author: 10

Main journals

Revue française d'allergologie 64
Ann Dermatol Venereol 41
Annales de dermatologie et de vénéréologie, FMC 27
Annales de Dermatologie et de Vénéréologie - FMC 22
Contact Dermatitis 21

Best Journals

JAMA Intern Med 1
Lancet Respir Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Allergic Contact Cheilitis due to Vitamin E Derivatives in Lipstick.
PMID 42900007 — vitamins, vitamin e, cheilitis, dermatitis, contact		Contact Dermatitis20260
Risk Factors and Therapeutic Consequences of Virologic Failure With Long-Acting Cabotegravir Plus Rilpivirine in the Dat'AIDS Cohort.
PMID 42873188 — viremia, rilpivirine, risk factors, therapeutics, communicable diseases, drug resistance, dolutegravir		Clin Infect Dis20260
Molluscum Contagiosum, Warts and Condylomas during JAK Inhibitor Therapy for Atopic Dermatitis: a Retrospective Series of 17 Cases.
PMID 42862144 — sexually transmitted diseases, molluscum contagiosum, dermatitis, warts, therapeutics, janus kinase inhibitors, dermatology, dermatitis, atopic		Acta Derm Venereol20260
Gaps in Current Chronic Spontaneous Urticaria (CSU) Management.
PMID 42828452 — syphilis, urticaria, therapeutics		Br J Dermatol20260
A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial.
PMID 42728529 — vitamin d, dermatitis, vitamins, phototherapy, genes, tat, therapeutics, dermatitis, atopic		Dermatol Ther (Heidelb)20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 6
N/A 5
Phase 2 5
Phase 1/Phase 2 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 10
Recruiting 3
Active not recruiting 2
Unknown 2
Not yet recruiting 1
Terminated 1

By type:

Interventional 15
Observational 4

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 1
multicentricup10 10

Main Topics

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A 52 week multi center randomized double blind placebo controlled basket study with an open label extension to investigate the efficacy safety and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1 antihistamines
2023-505739-12-01 — histamine antagonists, safety, urticaria, multiple chronic conditions, chronic inducible urticaria		Phase 3Active not recruiting2024
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial
2025-524078-40-00 — urticaria, multiple chronic conditions, therapeutics		Phase 3Recruiting2026
A 12 week randomized participant and investigator blinded placebo controlled exploratory study in adult participants with Chronic Urticaria to assess the efficacy and safety and explore the Mechanism of Action of remibrutinib (LOU064)
2024-516355-41-00 — chronic urticaria, safety, urticaria, chronic inducible urticaria		Phase 2Recruiting2025
Dupilumab step down strategy to maintain remission in adult and adolescents patients with atopic dermatitis a non inferiority randomized trial
2022-501179-23-00 — dermatitis, adolescent, dermatitis, atopic		Phase 4Active not recruiting2023
National Cohort of Patients With SITRAME Syndrome
NCT07168746 — rare diseases		N/ANot yet recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS